These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6404709)

  • 21. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 22. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 24. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E; Bianco I; Masi M
    Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract]   [Full Text] [Related]  

  • 25. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 26. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.
    Modell B; Khan M; Darlison M
    Lancet; 2000 Jun; 355(9220):2051-2. PubMed ID: 10885361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Desferrioxamine-B in the diagnosis of hemosiderotic states and in the therapy of thalassemia. Apropos of 2 cases].
    De Luca G; Faelli U; Petrussa I
    Minerva Pediatr; 1966 Oct; 18(32):1920-5. PubMed ID: 5993655
    [No Abstract]   [Full Text] [Related]  

  • 28. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC; Ng DM; Fong DY; Ha SY; Lau YL
    Am J Hematol; 2004 Aug; 76(4):398-404. PubMed ID: 15282678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of iron overload in Cooley's anemia.
    Cohen A; Mizanin J; Schwartz E
    Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 32. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 33. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF
    J Lab Clin Med; 1978 Aug; 92(2):141-3. PubMed ID: 681806
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V; Eleftheriou A; Malaventura C;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific chelation therapy with desferrioxamine in massive iron overdose.
    Levison LH
    Appl Ther; 1969 Mar; 11(3):153. PubMed ID: 5778632
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined vitamin D parathyroid defect in thalassemia major.
    Aloia JF; Ostuni JA; Yeh JK; Zaino EC
    Arch Intern Med; 1982 Apr; 142(4):831-2. PubMed ID: 6978696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive iron-chelation in thalassaemia.
    Pignatti CB; De Stefano P
    Br Med J; 1978 Nov; 2(6149):1432-3. PubMed ID: 719440
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiac disease in beta-thalassaemia major: Is it reversible?
    Atiq M; Bana M; Ahmed US; Bano S; Yousuf M; Fadoo Z; Khurshid M
    Singapore Med J; 2006 Aug; 47(8):693-6. PubMed ID: 16865210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance and beta cell function in chronically transfused patients of thalassemia major.
    Suvarna J; Ingle H; Deshmukh CT
    Indian Pediatr; 2006 May; 43(5):393-400. PubMed ID: 16735760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.